FDA approves release of recombinant interleukin-2 product.
D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000556:secondary; D000075202:Contraindications; D006801:Humans; D007376:Interleukin-2 / Q000009:adverse effects / Q000627:therapeutic use*; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000556:secondary; D014481:United States; D014486:United States Food and Drug Administration
D007376:Interleukin-2